Wednesday, July 8, 2026

biotech · Dystrophic Epidermolysis Bullosa · Autosomal Recessive Ichthyosis · KRYS

Krystal Biotech Netherlands

Krystal Biotech Netherlands patent portfolio — 14 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US HQ
2016 Founded
306 Employees
Public company Type
KRYS · NYSE Ticker
Company details
Status
Public
HQ
2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US
Founded
2016
Employees
306
Programs
14
Drugs
7
Patents
14
Intelligence · Patents

Krystal Biotech Netherlands patents

14 pharmaceutical patents indexed for Krystal Biotech Netherlands. 0 expire within 24 months.

Krystal Biotech Netherlands has 14 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12364775

    Viral vectors for cancer therapy

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12128122

    Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11918660

    Viral vectors for cancer therapy

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11865148

    Methods of delivering transgenes to the eye

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11779660

    Viral vectors for cancer therapy

    Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11717547

    Compositions and methods for the treatment of autosomal recessive congenital ichthyosis

    Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11642384

    Compositions and methods for the treatment of Netherton Syndrome

    Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11185564

    Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 10829529

    Compositions and methods for delivering CFTR polypeptides

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 10786438

    Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 10525090

    Compositions and methods for the treatment of autosomal recessive congenital ichthyosis

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10441614

    Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 10155016

    Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

    Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 9877990

    Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

    Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Krystal Biotech Netherlands have?

14 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Krystal Biotech Netherlands patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.